1. Gellert C, Schottker B, Brenner H. Smoking and all-cause mortality in older people: systematic review and meta-analysis. Arch Intern Med 2012;172:837-844.
2. Centers for Disease Control and Prevention (CDC). Smoking-attributable mortality, years of potential life lost, and productivity losses: United States, 2000-2004. MMWR Morb Mortal Wkly Rep 2008;57:1226-1228.
3. Siu AL. US Preventive Services Task Force. Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: US Preventive Services Task Force recommendation statement. Ann Intern Med 2015;163:622-634.
8. Jung-Choi KH, Khang YH, Cho HJ. Hidden female smokers in Asia: a comparison of self-reported with cotinine-verified smoking prevalence rates in representative national data from an Asian population. Tob Control 2012;21:536-542.
10. Schroeder SA. Depression, smoking, and heart disease: how can psychiatrists be effective? Am J Psychiatry 2011;168:876-878.
11. Jung KJ, Yun YD, Baek SJ, Jee SH, Kim IS. Smoking-attributable mortality among Korean adults, 2012. J Korea Soc Health Inform Stat 2013;38:36-48.
12. Jee SH, Jung KJ, Jeon C, Kim H, Yun YD, Kim IS. Smoking attributable risk and medical care cost in 2012 in Korea. J Korean Soc Health Stat 2014;39:25-41.
15. Song YM, Sung J, Cho HJ. Reduction and cessation of cigarette smoking and risk of cancer: a cohort study of Korean men. J Clin Oncol 2008;26:5101-5106.
16. Lee SK, Kweon HJ, Lim DJ, Kim KR, MO HH, Do HJ, Oh SW, Lym YL, Choi JK, Joh HK, Cho DY. The usefulness of heavy smoking index as a test for nicotine dependence. J Korean Acad Fam Med 2008;29:405-411.
17. 2008 PHS Guideline Update Panel, Liaisons, and Staff. Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice guideline executive summary. Respir Care 2008;53:1217-1222.
18. Patnode CD, Henderson JT, Thompson JH, Senger CA, Fortmann SP, Whitlock EPL. Behavioral counseling and pharmacotherapy interventions for tobacco cessation in adults, including pregnant women: a review of reviews for the US Preventive Services Task Force. Rockville: Agency for Health-care Research and Quality; 2015.
20. Mills EJ, Thorlund K, Eapen S, Wu P, Prochaska JJ. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation 2014;129:28-41.
21. Kim MH, Min S. Craving and treatment in smoking. J Korean Med Assoc 2011;54:401-408.
24. Cooper S, Taggar J, Lewis S, Marlow N, Dickinson A, White-more R, Coleman T. Smoking, Nicotine and Pregnancy (SNAP) Trial Team. Effect of nicotine patches in pregnancy on infant and maternal outcomes at 2 years: follow-up from the randomised, double-blind, placebo-controlled SNAP trial. Lancet Respir Med 2014;2:728-737.
25. van der Meer RM, Willemsen MC, Smit F, Cuijpers P. Smoking cessation interventions for smokers with current or past depression. Cochrane Database Syst Rev 2013;(8):CD006102.
26. Farley AC, Hajek P, Lycett D, Aveyard P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev 2012;1:CD006219.
27. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, Ascher J, Russ C, Krishen A, Evins AE. Neuro-psychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016;387:2507-2520.
28. US Food and Drug Administration. FDA Drug Safety Communication: FDA updates label for stop smoking drug Chantix (varenicline) to include potential alcohol interaction, rare risk of seizures, and studies of side effects on mood, behavior, or thinking [Internet] Silver Spring: Food and Drug Administration. cited 2016 Sep 7. Available from:
http://www.fda.gov/Drugs/DrugSafety/ucm436494.htm
29. Huang Y, Li W, Yang L, Jiang Y, Wu Y. Long-term efficacy and safety of varenicline for smoking cessation: a systematic review and meta-analysis of randomized controlled trials. J Public Health 2012;20:355-365.
32. Koegelenberg CF, Noor F, Bateman ED, van Zyl-Smit RN, Bruning A, O'Brien JA, Smith C, Abdool-Gaffar MS, Emanuel S, Esterhuizen TM, Irusen EM. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA 2014;312:155-161.
34. Boyle RG, Solberg LI, Fiore MC. Electronic medical records to increase the clinical treatment of tobacco dependence: a systematic review. Am J Prev Med 2010;39:6 Suppl 1. S77-S82.
35. DiClemente CC, Prochaska JO, Fairhurst SK, Velicer WF, Velasquez MM, Rossi JS. The process of smoking cessation: an analysis of precontemplation, contemplation, and preparation stages of change. J Consult Clin Psychol 1991;59:295-304.
36. West R. Time for a change: putting the transtheoretical (stages of change) model to rest. Addiction 2005;100:1036-1039.
37. Fu SS, van Ryn M, Sherman SE, Burgess DJ, Noorbaloochi S, Clothier B, Taylor BC, Schlede CM, Burke RS, Joseph AM. Proactive tobacco treatment and population-level cessation: a pragmatic randomized clinical trial. JAMA Intern Med 2014;174:671-677.
38. Solberg LI, Boyle RG, Davidson G, Magnan SJ, Carlson CL. Patient satisfaction and discussion of smoking cessation during clinical visits. Mayo Clin Proc 2001;76:138-143.
41. Bize R, Burnand B, Mueller Y, Rege-Walther M, Camain JY, Cornuz J. Biomedical risk assessment as an aid for smoking cessation. Cochrane Database Syst Rev 2012;12:CD004705.
42. Lindson-Hawley N, Aveyard P, Hughes JR. Reduction versus abrupt cessation in smokers who want to quit. Cochrane Database Syst Rev 2012;11:CD008033.
43. Lindson-Hawley N, Banting M, West R, Michie S, Shinkins B, Aveyard P. Gradual versus abrupt smoking cessation: a randomized, controlled noninferiority trial. Ann Intern Med 2016;164:585-592.
44. Baha M, Le Faou AL. Gradual versus abrupt quitting among French treatment-seeking smokers. Prev Med 2014;63:96-102.
45. Park SW. Evidence-based smoking cessation counseling: motivational intervention and relapse prevention. J Korean Med Assoc 2011;54:1036-1046.